Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaVitaDVA +0.12%91 3-Year Share Buyback Ratio is 8.80 as of Jun. 2026, which is 171% above its 10-year median of 3.25. GuruFocus rates DVA with a GF Score™ of 91/100 and a GF Value™ of $195.60 (Fairly Valued). The stock has 6 warning signs investors should review. Among 444 Healthcare Providers & Services companies, DaVita ranks better than 99.32% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. DaVita's current 3-Year Share Buyback Ratio was 8.80%.
The historical rank and industry rank for DaVita's 3-Year Share Buyback Ratio or its related term are showing as below:
DVA'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -29.7 Med: 3.25 Max: 16.4
Current: 8.8
During the past 13 years, DaVita's highest 3-Year Share Buyback Ratio was 16.40%. The lowest was -29.70%. And the median was 3.25%.
DVA's 3-Year Share Buyback Ratio is ranked better than 99.32% of 444
companies
in the Healthcare Providers & Services industry
Industry Median: -1.75
vs DVA: 8.80
DaVita (NYSE:DVA) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
DaVita 3-Year Share Buyback Ratio Related Terms
DVA vs EHC, UHS, ENSG: 3-Year Share Buyback Ratio Comparison
For the Medical Care Facilities subindustry, DaVita's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita 3-Year Share Buyback Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where DaVita's 3-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 8.80 mean?
DaVita (DVA) has a 3-Year Share Buyback Ratio of 8.80 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for DaVita and its competitors. This is 171% above median its historical median of 3.25. According to the industry distribution chart, DaVita ranks #3 out of 444 companies in the Healthcare Providers & Services industry, placing it in the top 0.7%.
Is DaVita's 3-Year Share Buyback Ratio too high?
DaVita's current 3-Year Share Buyback Ratio of 8.80 is 171% above median its 10-year median of 3.25. Based on the distribution chart, DaVita ranks #3 out of 444 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaVita has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaVita's 3-Year Share Buyback Ratio compare to EHC and UHS?
According to the Healthcare Providers & Services industry distribution chart, DaVita ranks #3 out of 444 companies for 3-Year Share Buyback Ratio. This places DaVita in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Healthcare Providers & Services company?
A good 3-Year Share Buyback Ratio depends on the Healthcare Providers & Services industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for DaVita and its competitors. DaVita's current 3-Year Share Buyback Ratio is 8.80, which is 171% above median its own 10-year median of 3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (DVA) is currently considered Fairly Valued. The stock's GF Value™ is $195.60, compared to a current price of $181.55 — trading 7.2% below its estimated fair value. The current 3-Year Share Buyback Ratio is 8.80, which is 171% above median its 10-year median of 3.25. DaVita's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For DaVita (DVA), the current 3-Year Share Buyback Ratio is 8.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (DVA) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be undervalued.
The current stock price of $181.55 is trading 7.2% below its estimated GF Value™ of $195.60.
GuruFocus considers DaVita to be Fairly Valued.
Key valuation signals for DVA:
3-Year Share Buyback Ratio: 8.80 (171% above median its 10-year median of 3.25)
GF Value™: $195.60 vs. price of $181.55 (7.2% below fair value)
No single metric tells the full story. See the DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
91GF Score
Get the complete analysis for DVA
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVA has been successfully added to your 
